Immuneering Corporation
IMRX
$1.54
$0.096.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.01M | 3.69M | 4.01M | 4.25M | 4.12M |
| Depreciation & Amortization | 7.30K | 7.30K | 7.30K | 7.30K | 7.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.48M | 18.56M | 15.27M | 14.91M | 15.33M |
| Operating Income | -15.48M | -18.56M | -15.27M | -14.91M | -15.33M |
| Income Before Tax | -15.05M | -18.05M | -14.60M | -14.08M | -14.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.05M | -18.05M | -14.60M | -14.08M | -14.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.05M | -18.05M | -14.60M | -14.08M | -14.31M |
| EBIT | -15.48M | -18.56M | -15.27M | -14.91M | -15.33M |
| EBITDA | -15.39M | -18.46M | -15.18M | -14.82M | -15.23M |
| EPS Basic | -0.42 | -0.58 | -0.49 | -0.47 | -0.49 |
| Normalized Basic EPS | -0.26 | -0.36 | -0.31 | -0.30 | -0.31 |
| EPS Diluted | -0.42 | -0.58 | -0.49 | -0.47 | -0.49 |
| Normalized Diluted EPS | -0.26 | -0.36 | -0.31 | -0.30 | -0.31 |
| Average Basic Shares Outstanding | 35.53M | 31.05M | 29.84M | 29.65M | 29.37M |
| Average Diluted Shares Outstanding | 35.53M | 31.05M | 29.84M | 29.65M | 29.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |